Clinical trialNCT05272384RecruitingPhase 1Interventional

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

SponsorNational Cancer Institute (NCI)Enrollment32Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Hodgkin Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Catherine S Diefenbach
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Active, not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Matthew Mei
Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Joseph M. Tuscano
Recruiting
Yale University
New Haven, Connecticut, United States
Tarsheen Sethi
Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Justin P. Kline
Recruiting
Uc Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States
Justin P. Kline
Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States
Justin P. Kline
Recruiting
Nyu Langone Hospital - Long Island
Mineola, New York, United States
Catherine S. Diefenbach
Recruiting
Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Catherine S. Diefenbach
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Nov 2022
Primary completion: 28 Jun 2027
Completion: 28 Jun 2027
Last update posted: 13 May 2026
Registered enrollment: 32
Registry id: NCT05272384

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.